R_2 is phenyl substituted with 1 to 3 substituents selected from the group consisting of a halogen, a hydroxyl, a methoxy, a benzyloxy, a phenoxy, a trifluoromethyl, an isopropyl, and a thiomethyl group, napthyls and substituted napthyls

or a pharmaceutically acceptable salt thereof.

7. (Amended) The antimycobacterial compound according to claim 21 where R_1,R_2 is

$(CH_2)_4$, $(CH_2)_6$, $4\text{-}C_6H_8NNHCO\text{-}4\text{-}C_5H_4N$.

8. (Amended) The antimycobacterial compound according to claim 21 where R_1,R_2 is





or



17. (Amended) A method for producing an antimycobacterial compound of the formula:



I

wherein R_1 is H; and

wherein R_2 is phenyl substituted with 1 to 3 substituents selected from the group consisting of a halogen, a hydroxyl, a methoxy, a benzyloxy, a phenoxy, a trifluoromethyl, an isopropyl, and a thiomethyl group, napthyls and substituted napthyls or

wherein R_1R_2 = optionally substituted carbocyclic groups;

which comprises:

refluxing



(1)

with absolute ethanol to produce a solution;

adding a carbonyl compound comprising the formula of:

R_3COR_4 **(2)**

wherein R_3 = H or CH_3; and

wherein R_4 = C_1 to C_{14} alkyl, C_2 to C_{10} substituted alkyl, C_2 to C_{10} alkenyl, C_2 to C_9 substituted alkenyl, C_2 to C_9 substituted dialkenyl, C_3 to C_7 cycloalkyl, C_3 to C_7 substituted cycloalkyl, phenyl, substituted phenyl, C_7 to C_{16} phenylalkyl, C_7 to C_{16} substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo, hydroxy, amino, or carboxy; or

wherein R_3R_4 = C_4 to C_8 cycloalkyl or C_4 to C_{10} substituted cycloalkyl;

to the solution to produce a reaction mixture;

distilling the reaction mixture;

adding diethyl ether to the reaction mixture;

filtering the reaction mixture; and

drying the filtrate to produce **I**.

Please add the following claims:

21. (New) An antimycobacterial compound of the formula:



I

wherein R_1 , R_2 is optionally substituted carbocylic groups or a pharmaceutically acceptable salt thereof.

22. (New) The antimycobacterial compound according to claim 1 wherein R_1 is H; and R_2 = 4-*iso*-$C_3H_7C_6H_4$, 2,5-di(Cl)C_6H_3, 2,3,5-tri(F)C_6H_2, 2-F-4-$CF_3C_6H_3$, 3,4,5-tri(F)C_6H_2, 2-Cl-6-CH_3O-*iso*-C_9H_4N, 2-F-3-Cl-6-$CF_3C_6H_2$, 2,4-di(CF_3)C_6H_3, 2,6-di(F)-3-Cl-C_6H_2, 2-F-3-Cl-5-CF_3-C_6H_2, 2-F-5-Br-C_6H_3, 2-CH_3S-C_6H_4, 2-O-$C_7H_7C_6H_4$, 3-O-$C_7H_7C_6H_4$, 4-O-$C_7H_7C_6H_4$, 2,4,5-tri(F)C_6H_2, 2-F-5-I-C_6H_3, 2,3,4-tri(OH)C_6H_2, 4-C_6H_4-CH=NNHCO-4-C_5H_4N, 4-C_6H_4-O-$CH_2CH_2CH_2CH_3$, 4-$C_6H_4NO_2$, 2-C_6H_4OH, 4-OH-3-$OCH_3C_6H_3$, 4-$C_6H_4OCH_3$, 3-$C_6H_4OCH_3$, 4-C_6H_4F, 3,5-di(CH_3)-4-O-C_7H_7, 2-F-4-$OCH_3C_6H_3$, 2-ClC_6H_4, 4-BrC_6H_4, 3-$C_6H_4NO_2$, 4-$C_6H_4O(CH_2)_5CH_3$, 2-Cl-5-$NO_2C_6H_3$, 4-Cl-3-$NO_2C_6H_3$, 2-$C_6H_4NO_2$, 2-6- di(Cl)C_6H_3, 2,3-di(Cl)C_6H_3, 3,4-di(F)C_6H_3, 2,6-di(F)C_6H_3, 3,4-di(Cl)C_6H_3 or 4-C_6H_4Cl.

23. (New) The antimycobacterial compound according to claim 1 wherein R_1 is H; and

R_2 =







REMARKS

The Office Action dated January 29, 2002 has been received and carefully considered.

The interview with the Examiner on April 24, 2002 is acknowledged and appreciated. It is believed the Examiner Interview Summary Record sets forth the substance of the interview.